Stockscreener 앱 받기
410.35
0.46%
1.88
전일 마감가:
$408.47
열려 있는:
$409.4
하루 거래량:
1.87M
Relative Volume:
1.36
시가총액:
$59.15B
수익:
$2.50B
순이익/손실:
$-226.32M
주가수익비율:
-250.03
EPS:
-1.6412
순현금흐름:
$71.51M
1주 성능:
-0.54%
1개월 성능:
+26.20%
6개월 성능:
+97.30%
1년 성능:
+156.13%
1일 변동 폭
$401.00
$413.36
1주일 범위
$401.00
$427.47
52주 변동 폭
$160.59
$427.47
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | William Blair | Outperform |
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Australia
Natera, Inc. (NTRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Natera stock hits all-time high at 422.19 USD - Investing.com
$1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today - Benzinga
Hewlett Packard, Natera, UnitedHealth Group: CNBC ‘Final Trades’UnitedHealth Group (NYSE:UNH) - Benzinga
Form 4 Natera Inc For: 27 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September - Investing.com India
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera(NTRA.US) Director Sells US$7.01 Million in Common Stock - Moomoo
RBC Capital raises Natera stock price target on MRD testing growth By Investing.com - Investing.com South Africa
Final Trades: Hewlett Packard, Natera and UnitedHealth - CNBC
Natera options flow shows 12.6:1 put/call ratio near 52-week high - Investing.com
NTRA Maintained by RBC Capital -- Price Target Raised to $460 - GuruFocus
RBC Capital raises Natera stock price target on MRD testing growth - Investing.com
Natera Is Maintained at Outperform by RBC Capital - moomoo.com
RBC Capital maintains Outperform rating on Natera, $460 price target - TradingView
Natera’s Critical Pivot to Oncology - Nanalyze
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating - marketscreener.com
Natera Inc (NTRA) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Svetlana Nikic Celebrates Natera’s Signatera Milestone in Japan - Oncodaily
Natera stock gains 2.75 percent after Japan test approval - AD HOC NEWS
Has Natera (NTRA) Run Ahead Of Fair Value After Its Japan Signatera Approval? - simplywall.st
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar - Yahoo Finance
Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval - insideprecisionmedicine.com
Form 144 Natera For: 23 September By Investing.com - Investing.com Canada
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Yahoo Finance
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera, Inc.Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Is Natera (NTRA) Stock Soaring Today - Yahoo Finance
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 - GuruFocus
Behavioral Patterns of NTRA and Institutional Flows - Stock Traders Daily
Natera Inc stock reaches all-time high at 373.58 USD By Investing.com - Investing.com Nigeria
Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement - TradingKey
Natera gains as fresh Signatera lung cancer data and upbeat analyst sentiment support shares - Quiver Quantitative
NTRA Looks 68.7% Overvalued on GF Value™ - gurufocus.com
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - Finviz
Natera’s Signatera Receives Japanese Approval as CDx for Muscle-Invasive Bladder Cancer - GenomeWeb
Natera Inc stock reaches all-time high at 373.58 USD - Investing.com
Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027 - TradingView
Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’ - Benzinga
A cancer test receives its second Japan approval in three months to guide bladder-cancer treatment. - Stock Titan
Enterprise value to EBITDA ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA.CI - TradingView
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
0.96%
자본화:
|
볼륨(24시간):